---
title: "TScan Therapeutics Faces Loss of Key Amgen Partnership"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296272693.md"
description: "TScan Therapeutics announced that Amgen has exercised its right to terminate their May 2023 research collaboration and license agreement, effective November 10, 2026. The termination carries no early penalty for TScan, but results in the lapse of Amgen's exclusive worldwide license. TScan does not expect further milestone or royalty payments from this deal, marking a significant setback to its partnership-driven revenue model given potential milestones exceeding $500 million."
datetime: "2026-08-18T21:32:22.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296272693.md)
  - [en](https://longbridge.com/en/news/296272693.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296272693.md)
---

# TScan Therapeutics Faces Loss of Key Amgen Partnership

TScan Therapeutics ( (TCRX) ) has shared an announcement.

On August 12, 2026, TScan Therapeutics said that Amgen had exercised its right to terminate their May 8, 2023 research collaboration and license agreement focused on using TScan’s target discovery platform to identify T-cell antigens in Crohn’s disease patients. The termination, which carries no early penalty for TScan, becomes effective November 10, 2026, at which point Amgen’s exclusive worldwide license to develop and commercialize collaboration-derived product candidates will lapse.

TScan will use commercially reasonable efforts to promptly wind down its activities under the current research plan and, following termination, does not expect to receive additional milestone or royalty payments tied to the Amgen deal, absent further exploitation of product candidates by Amgen or its partners. The loss of potential success-based milestones of more than $500 million and future tiered royalties underscores a setback to TScan’s partnership-driven revenue model and may alter expectations for long‑term collaboration economics for stakeholders.

The most recent analyst rating on (TCRX) stock is a Buy  
with a $7.00 price target.  
To see the full list of analyst forecasts on TScan Therapeutics stock,  
see the TCRX Stock Forecast page.

**Spark’s Take on TCRX Stock**

According to Spark, TipRanks’ AI Analyst, TCRX is a Neutral.

The score is primarily held down by weak financial performance (large ongoing losses and heavy cash burn with a weakening equity base) and bearish technical positioning (trading below major moving averages). Corporate events provide some offset via positive progress toward a pivotal trial, but the expanded authorized share count elevates dilution risk, while valuation is constrained by negative earnings and no dividend support.

To see Spark’s full report on TCRX stock,  
click here.

**More about TScan Therapeutics**

TScan Therapeutics, Inc. is a biotechnology company that leverages a proprietary T-cell target discovery platform to identify antigens recognized by T-cells, with applications in immune-mediated diseases such as Crohn’s disease. The company focuses on partnering its discovery capabilities with larger biopharmaceutical firms to advance potential therapeutic product candidates into development and commercialization.

**Average Trading Volume:** 624,468

**Technical Sentiment Signal:** Sell

**Current Market Cap:** $52.79M

Find detailed analytics on TCRX stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [AMGN.US](https://longbridge.com/en/quote/AMGN.US.md)
- [TCRX.US](https://longbridge.com/en/quote/TCRX.US.md)

## Related News & Research

- [Amgen Inc. $AMGN Shares Purchased by Simplicity Wealth LLC](https://longbridge.com/en/news/296332019.md)
- [Amgen Inc. $AMGN Shares Bought by Bridgewater Advisors Inc.](https://longbridge.com/en/news/296072511.md)
- [Hussman Strategic Advisors Inc. Has $3.04 Million Stock Position in Amgen Inc. $AMGN](https://longbridge.com/en/news/295999249.md)
- [Abner Herrman & Brock LLC Decreases Stock Holdings in Amgen Inc. $AMGN](https://longbridge.com/en/news/295293655.md)
- [Altria Group, Inc. $MO Shares Bought by Kestra Private Wealth Services LLC](https://longbridge.com/en/news/295998106.md)